1. Naucler, P, Ryd, W, Törnberg, S, et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–1597.
Google Scholar | Crossref | Medline | ISI2. Rijkaart, DC, Berkhof, J, Rozendaal, L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78–88.
Google Scholar | Crossref | Medline | ISI3. Ronco, G, Giorgi Rossi, P, Carozzi, F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249–257.
Google Scholar | Crossref | Medline | ISI4. Kitchener, HC, Gilham, C, Sargent, A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011; 47: 864–871.
Google Scholar | Crossref | Medline | ISI5. Cuzick, J, Clavel, C, Petry, KU, et al. Overview of the european and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095–1101.
Google Scholar | Crossref | Medline | ISI6. Ronco, G, Dillner, J, Elfström, KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four european randomised controlled trials. Lancet 2014; 383: 524–532.
Google Scholar | Crossref | Medline | ISI7. Dijkstra, MG, van Zummeren, M, Rozendaal, L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 2016; 355: i4924.
Google Scholar | Medline8. Van Rosmalen, J, de Kok, IM, van Ballegooijen, M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012; 119: 699–709.
Google Scholar | Crossref | Medline9. Accetta, G, Biggeri, A, Carreras, G, et al. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. J Med Screen 2010; 17: 181–189.
Google Scholar10. Jansen, EEL, Naber, SK, Aitken, CA, et al. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study jansen. BJOG 2021; 128: 573–582,
Google Scholar | Crossref | Medline11. von Karsa, L, Arbyn, M, DeVuyst, H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus 2015; 1: 22–31.
Google Scholar12. Meijer, CJ, Berkhof, H, Heideman, DA, et al. Validation of high-risk HPV tests for primary cervical screening. J. Clin. Virol 2009; 46: S1–S4.
Google Scholar | Crossref | Medline13. Rebolj, M, van Ballegooijen, M, Berkers, LM, et al. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120: 806–812.
Google Scholar | Crossref | Medline | ISI14. Ronco, G, Accetta, G, Angeloni, C, et al. Ricerca del dna di papillomavirus umano (HPV). Epidemiol Prev 2012; 36: 1–72.
Google Scholar15. Arbyn, M, Anttila, A, Jordan, J, et al. European guidelines for quality assurance in cervical cancer screening: second edition. Ann Oncol 2010; 21: 448–458.
Google Scholar | Crossref | Medline | ISI16. Zappa, M, Carozzi, F, Giordano, L, et al. The diffusion of screening programmes in Italy, years 2011-2012. Epidemiol Prev 2015; 39(3 Suppl 1): 5–8.
Google Scholar | Medline17. Zorzi, M, Giorgi Rossi, P. Gruppo di lavoro GISCI sugli indicatori dello screening con test HPV primario. Indicators for monitoring screening programs with primary HPV test Epidemiol Prev 2017; 41: 1–32.
Google Scholar | Medline18. Carozzi, F, Del Mistro, A, Cuschieri, K, et al. HPV Testing for primary cervical screening: laboratory issues and evolving requirements for robust quality assurance. J Clin Virol 2016; 76: S22–S28.
Google Scholar | Crossref | Medline19. Del Mistro, A, Passamonti, U, Ronco, G, et al. Documento ONS-GISCI “Test Validati per lo screening HPV” Rapporto N. 6. https://www.gisci.it/documenti/documenti_gisci/Rapporto%20N.6_Test%20HPV%20Validati_8mar21.pdf. Document of GISCi, 2021; 1-16
Google Scholar20. Bouvard, V, Baan, R, Straif, K, et al. WHO International agency for research on cancer monograph working group - A review of human carcinogens--part B: biological agents. Lancet Oncol 2009; 10: 321–322.
Google Scholar | Crossref | Medline | ISI21. Gillio Tos, A, Macrì, L, Troni, GM, et al. La citologia di triage nei programmi di screening con HPV come test primario: indicazioni per l'Implementazione delle linee guida europee 2015. https://www.gisci.it/documenti/documenti_gisci/LA_CITOLOGIA_DI_TRIAGE_NEI_PROGRAMMI_DI_SCREENING-2020.pdf Document of GISCi 2019; 1-16
Google Scholar22. Gillio Tos, A, De Marco, L, Del Mistro, A, et al. EXECUTIVE SUMMARY del documento RACCOMANDAZIONI SUL TEST HR-HPV COME TEST DISCREENING PRIMARIO. https://www.gisci.it/documenti/documenti_gisci/EXECUTIVE-SUMMARY-2019-web.pdf. Document of GISCi 2019; 1-10
Google Scholar23. Confortini, M, Ronco, G, Carozzi, F, et al. Utilizzo del test HPV-HR nel triage delle ASC-US, delle LSIL in donne con più di 35 anni, nel follow-up delle donne con citologia ASC-US+ dopo un approfondimento di secondo livello negativo per CIN2+ e nel follow-up dopo trattamento delle lesioni CIN2-3. https://gisci.it/documenti/documenti_gisci/Utilizzo_test_HPV-HR_2018_def2.pdf. Document of GISCi 2018; 1-28
Google Scholar24. Iossa, A, Carozzi, F, Mantellini, P. and the “Gruppo di lavoro regionale per la prevenzione del tumore della cervice uterina”. Protocollo regionale per la gestione delle citologie anormali e del follow-up post-trattamento delle lesioni precancerose della cervice uterina. Rapporto Annuale Programmi Screening 2013; 14: 104-117. https://www.ispro.toscana.it/sites/default/files/Documenti/monografie/14%C2%B0%20Rapporto%20Annuale%20Programmi%20Screening_2013.pdf
Google Scholar25. Zorzi, M, Del Mistro, A, Farruggio, A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG 2013; 120: 1260–1267.
Google Scholar | Crossref | Medline | ISI26. Pasquale, L, Giorgi Rossi, P, Carozzi, F, et al. Cervical cancer screening with HPV testing in the valcamonica (Italy) screening programme. J Med Screen 2015; 22: 38–48.
Google Scholar | SAGE Journals | ISI27. Ronco, G, Giorgi Rossi, P, Carozzi, F, et al. Results at recruitment From a randomized controlled trial comparing human papillomavirus testing alone With conventional cytology as the primary cervical cancer screening Test. J Natl Cancer Inst 2008; 100: 492–501.
Google Scholar | Crossref | Medline28. Baussano, I, Franceschi, S, Gillio-Tos, A, et al. Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infect Dis 2013; 13: 238.
Google Scholar | Crossref | Medline29. Bergeron, C, Giorgi Rossi, P, Cas, F, et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015; 107: dju423,
Google Scholar | Crossref | Medline30. Rebolj, M, Rimmer, J, Denton, K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 2019; 6: 364:l240.
Google Scholar31. Thomsen, LT, Kjaer, SK, Munk, C, et al. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: a real-world comparison of HPV testing versus cytology. Acta Obstet Gynecol Scand 2021; 100(3): 394–402,
Google Scholar | Crossref | Medline32. Kyrgiou, M, Athanasiou, A, Kalliala, IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017; 2: 11 CD012847.
Google Scholar33. Pasquale, L, Giorgi Rossi, P, Carozzi, F, et al. HPV Screening performance indicators in women who previously tested HPV-negative: the second round of vallecamonica screening programme, northern Italy. J Med Screen 2020; 27: 207–214.
Google Scholar | SAGE Journals | ISI34. Simms, KT, Steinberg, J, Caruana, M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol 2019; 20: 394–407.
Google Scholar | Crossref | Medline35. Franco, EL, Mahmud, SM, Tota, J, et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Medical Res 2009; 40: 478–485.
Google Scholar | Crossref | Medline | ISI36. Arbyn, M, Rezhake, R, Yuill, S, et al. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. BJC 2020; 122: 1577–1579.
Google Scholar | Crossref | Medline